Brain metastasis in lung cancer: Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging;Hirnmetastasen beim Bronchialkarzinom: Vergleich der zerebralen MRT mit dem 18F-FDGPET/ CT beim initialen Staging für die Diagnose

NuklearMedizin

Volumn 50, Issue 3, 2011, Pages 101-106

  Kruger S ^a,b   Mottaghy, F M ^a,b   Buck, A K ^a,c   Maschke, S ^a   Kley, H ^a   Frechen, D ^b   Wibmer, T ^a   Reske, S N ^a   Pauls, S ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Brain metastasis; Lung cancer; Mri; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; IOPROMIDE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; GERMANY; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79957651629     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0338-10-07     Document Type: Article

References (33)

1. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672.
2. Bonnette P, Puyo P, Gabriel C et al. the Groupe Thorax. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001; 119: 1469-1475.
3. Earnest F, Ryn JH, Miller GM et al. Suspected nonsmall cell lung cancer: Incidence of occult brain and skeletal metastases and effectiveness of imaging for detection. Pilot study. Radiology 1999; 211: 137-145.
4. Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedures for patients with non small cell lung cancer. Chest 1994;106: 1025-1029.
5. Goeckenjan G, Sitter H, Thomas M et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Be-atmungsmedizin und der Deutschen Krebsgesell-schaft. Pneumologie 2010; 64 (Suppl 2): e1-e164.
6. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin 2009; 48: 59-69.
7. Hochstenbag MMH, Twijnstra A, Hofman P et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 2003; 42: 189-193.
8. I H, Lee JI, Nam DH et al. Surgical treatment of non-small cell lung cancer with isolated synchronous brain metastases. J Korean Med Sci 2006; 21: 236-241.
9. Jena A, Taneja S, Talwar V, Sharma JB. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol 2008; 3: 140-144.
10. Kormas P, Bradshaw JR, Jeyasingham K. Preoperative computed tomography of the brain in nonsmall cell bronchogenic carcinoma. Thorax 1992; 47: 106-108.
11. Kotzerke J, Oehme L, Lindner O, Hellwig D. Positron emission tomography 2008 in Germany - results of the query and current status. Nuklearmedizin 2010; 49: 58-64.
12. Krüger S, Buck AK, Mottaghy FM et al. Detection of bone metastases in patients with lung cancer: 99mTc- MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 1807-1812.
13. Lardinois D, Weder W, Hany TF et al. Staging of non-small-lung cancer with integrated positronemission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507.
14. Lee HY, Lee KS, Kim BT et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci 2009; 24: 1132-1138.
15. th Annual Meeting of American Society of Clinical Oncology. Orlando: American Society of Clinical Oncology; 2002: 375-382.
16. Mujoomdar A, Austin JH, Malhotra R et al. Clinical predictors of metastatic disease to the brain fromn non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007; 242: 882-888.
17. Ohno Y, Koyama H, Nogami M et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007; 26: 498-509.
18. Pfister DG, Johnson DH, Azzoli ChG et al. American Society of Clinical Oncology. Treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
19. Salbeck R, Grau HC, Artmann H. Cerebral tumorstaging in patients with bronchial carcinoma by computed tomography. Cancer 1990; 66: 2007-2011.
20. Salvatierra A, Baamonde C, Llamas JM et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97: 1052-1058.
21. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44: 275-281.
22. Schouten LJ, Rutten J, Huveneers HAM Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698-2705.
23. Silvestri GA, Gould MK, Margolis ML et al. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced based clinical practice guidelines (2nd ed). Chest 2007; 132 (3 Suppl): S178-S201.
24. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A metaanalysis. Am J Respir Crit Care Med 1995; 152: 225-230.
25. Silvestri GA, Tanoue LT, Margolis ML et al. The noninvasive staging of non-small cell lung cancer. Chest 2003; 123: 147S-156S.
26. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6: 1474-1480.
27. Sze G, Shin J, Krol G et al. Intraparenchymal brain metastases: MR Imaging versus contrast-enhanced CT. Radiology 1988; 168: 187-194.
28. The American Thoracic Society and The European Respiratory Society. Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 1997; 156: 320-332.
29. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer. A review of the current evidence. Chest 2003; 123: 137S-146S.
30. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006; 24: 1289-1294.
31. Yi CA, Shin KM, Lee KS et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008; 248: 632-642.
32. Yokoi K, Kamiya N, Matsuguma H et al. Detection of brain metastasis in potentially operable nonsmall cell lung cancer. A comparison of CT and MRI. Chest 1999; 115: 714-719.
33. Zabel A, Milker-Zabel S, Thilmann C et al. Treatment of brain metastasis in patients with non-small cell lung cancer (NSCLC) by stereotactic linacbased radiosurgery: prognostic factors. Lung Cancer 2002; 37: 87-94.